Gilead has named AbbVie and Pfizer veteran Michael Boyd as VP of government affairs and policy.
Boyd joined Gilead in October. He is overseeing global government affairs and policy strategy across markets in North America, Europe, Asia, Japan, and Latin America.
For four years, Boyd was VP of global government affairs at AbbVie, where he built the government affairs team after its spin off from Abbott. After leaving AbbVie in 2017, Boyd launched his own public and government affairs consulting firm, Hillbrook Strategies. He has also had two stints at Pfizer, including nine years working in government relations, then returning as VP of international public affairs.
Earlier in his career, Boyd served as acting director general of the International Federation of Pharmaceutical Manufacturers and Associations, VP of public affairs international at Schering-Plough, and as a legislative assistant on Capitol Hill. He began his career in legal roles at GE.
Gilead has seen high executive turnover this year, with its CEO, chairman, chief medical officer, and R&D leaders all exiting. In August, the company made several appointments, including Laura Hamill, previously with Amgen, as commercial head and Gregg Alton as chief patient officer.
The maker of Harvoni and Sovaldi posted better-than-expected Q3 earnings last month and increased its revenue guidance for this year.
